INNV
InnovAge Holding Corp.
INNV has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over INNV overall, supported by stronger fundamentals and stronger valuation.
INNV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
INNV's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INNV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $9.40 | — |
| Cheap | 44x | $2.62 | -72% |
| Fair | 87x | $5.22 | -44% |
| Expensive | 150x | $8.97 | -4.6% |
| Current | 157x | $9.40 | — |
Historical ranges are pointers, not guarantees.
INNV's PE is in its expensive range at 157x. If earnings grow as analysts expect, today's price would be 21x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over INNV in the historical PE scenario, which offers more potential upside but is not a forecast.
INNV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for INNV, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
INNV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.45 | +655% |
| Q3 2026 | $0.06 | +$0.18 |
| Q2 2026 | -$0.02 | +$0.20 |
| Q1 2026 | -$0.08 | +$0.15 |
| Q4 2025 | $0.06 | +$0.25 |
| Q3 2025 | -$0.12 | $0.00 |
| Q2 2025 | -$0.22 | -$0.06 |
| Q1 2025 | -$0.23 | $0.00 |
| Q4 2024 | -$0.19 | +$0.05 |
INNV has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
INNV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $264.8M | +12% |
| Q2 2026 | $262M | +18% |
| Q1 2026 | $251.9M | +15% |
| Q4 2025 | $239.7M | +15% |
| Q3 2025 | $236.1M | +15% |
| Q2 2025 | $221.4M | +11% |
| Q1 2025 | $218.1M | +13% |
| Q4 2024 | $209M | +11% |
INNV's revenue has grown year over year for 14 quarters in a row: $265M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.6% | +4.1 points |
| Q2 2026 | 3.9% | +4.8 points |
| Q1 2026 | -12% | -6.9 points |
| Q4 2025 | 5.5% | +12 points |
| Q3 2025 | 3.5% | +5.9 points |
| Q2 2025 | -1% | +1.5 points |
| Q1 2025 | -4.7% | -1.7 points |
| Q4 2024 | -6% | -5.1 points |
INNV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INNV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
INNV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.8M | +$25.9M |
| Q2 2026 | $17M | +85% |
| Q1 2026 | $14.5M | -33% |
| Q4 2025 | $19M | +251% |
| Q3 2025 | -$153K | +$9.6M |
| Q2 2025 | $9.2M | +$10.6M |
| Q1 2025 | $21.7M | +611% |
| Q4 2024 | $5.4M | +$16.3M |
INNV has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
INNV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.4M shares |
| 1 year | +0.2% | +308K shares |
| 3 years | +0.9% | +1.3M shares |
| 5 years | +1.1% | +1.6M shares |
| Available history | +1.2% | +1.6M shares |
INNV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q4 2020 | — |
| Q3 2020 | $77.6M |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INNV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.0x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -3.1x | Net Cash |
| Q3 2024 | 9.3x | High |
| Q2 2022 | -11.8x | Net Cash |
| Q1 2022 | -4.0x | Net Cash |
INNV has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over INNV on leverage, with a lower net debt burden relative to earnings.
INNV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 20.7 | Neutral |
INNV's weekly RSI is 50 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INNV PE vs Healthcare Sector
| Metric | INNV | Sector median | Relative |
|---|---|---|---|
| PE | 157x | 26x | 506% above |
| PE % | 90 | 35 | 55 pts above |
INNV is trading at 157x earnings, a 506% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over INNV on valuation relative to its sector.
INNV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.13 | 3% above |
| 20 week MA | $10.4 | 9.2% below |
| 50 week MA | $8.59 | 9.4% above |
| 100 week MA | $6.26 | 50% above |
| 200 week MA | $6.08 | 55% above |
INNV's trend is mixed: it's above four of its five weekly moving averages, and 55% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INNV on trend strength, trading above more of its moving averages.
INNV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $5.31 | -78% |
| 2022 | $5.31 | $6.85 | +29% |
| 2023 | $6.85 | $6.00 | -12% |
| 2024 | $6.00 | $3.92 | -35% |
| 2025 | $3.92 | $5.54 | +41% |
| 2026 YTD | $5.54 | $9.40 | +70% |
INNV is up 70% so far in 2026, after finishing lower in three of the previous five years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INNV on returns for 2026, with the stronger performance.